{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:35Z","timestamp":1787020835130,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIA\/NIH","award":["P30 AG072946, R01 AG061111, RF1 NS118584, R01 AG057187"],"award-info":[{"award-number":["P30 AG072946, R01 AG061111, RF1 NS118584, R01 AG057187"]}]},{"name":"NIA\/NIH","award":["P30 AG072946, R01 AG061111, RF1 NS118584, R01 AG057187"],"award-info":[{"award-number":["P30 AG072946, R01 AG061111, RF1 NS118584, R01 AG057187"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dementia and cancer are multifactorial, widely-feared, age-associated clinical syndromes that are increasing in prevalence. There have been major breakthroughs in clinical cancer research leading to some effective treatments, whereas the field of dementia has achieved comparatively limited success in clinical research. The lessons of cancer research may help those in the dementia research field in confronting some of the dilemmas faced when the clinical care regimen is not entirely safe or efficacious. Cancer clinical trials have assumed that untreated individuals with cancer are at high risk for morbidity and mortality after primary diagnoses. Thus, patients deserve a choice of clinical interventions, either standard of care or experimental, even if the benefits are not certain and the therapy\u2019s side effects are potentially severe. The prognosis for many individuals at risk for dementia carries a correspondingly high level of risk for both mortality and severe morbidity, particularly\u00a0if one focuses on \u201chealth-span\u201d rather than lifespan. Caregivers and patients can be strongly impacted by dementia and the many troubling associated symptoms that often go well beyond amnesia. Polls, surveys, and a literature on \u201cdementia worry\u201d strongly underscore that the public fears dementia. While there are institutional and industry hurdles that complicate enrollment in randomized trials, the gravity of the future morbidity and mortality inherent in a dementia diagnosis may require reconsideration of the current protective stance that limits the freedom of at-risk individuals (either symptomatic or asymptomatic) to participate and potentially benefit from ongoing clinical research. There is also evidence from both cancer and dementia research that individuals enrolled in the placebo arms of clinical trials have unexpectedly good outcomes, indicating that participation in clinical trial can have medical benefits to enrollees. To highlight aspects of cancer clinical research that may inform present and future dementia clinical research, this review highlights three main themes: the risk of side effects should be weighed against the often dire consequences of non-treatment; the desirability of long-term incremental (rather than \u201cmagic bullet\u201d) clinical advances; and, the eventual importance of combination therapies, reflecting that the dementia clinical syndrome has many underlying biological pathways.<\/jats:p>","DOI":"10.1186\/s13195-024-01532-6","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T08:06:48Z","timestamp":1724314008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cancer research provides a model for advancing clinical trials in dementia in the era of disease-modifying Alzheimer\u2019s-type dementia therapies"],"prefix":"10.1186","volume":"16","author":[{"given":"Gregory A.","family":"Jicha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne M.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"issue":"2","key":"1532_CR1","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/alz.12737","volume":"19","author":"JB Langbaum","year":"2023","unstructured":"Langbaum JB, Zissimopoulos J, Au R, Bose N, Edgar CJ, Ehrenberg E, et al. Recommendations to address key recruitment challenges of Alzheimer\u2019s disease clinical trials. Alzheimers Dement. 2023;19(2):696\u2013707.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1532_CR2","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1377\/hlthaff.2013.1314","volume":"33","author":"JL Watson","year":"2014","unstructured":"Watson JL, Ryan L, Silverberg N, Cahan V, Bernard MA. Obstacles and opportunities in Alzheimer\u2019s clinical trial recruitment. Health Aff (Millwood). 2014;33(4):574\u20139.","journal-title":"Health Aff (Millwood)"},{"issue":"6676","key":"1532_CR3","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1126\/science.adj9255","volume":"382","author":"TE Golde","year":"2023","unstructured":"Golde TE, Levey AI. Immunotherapies for Alzheimer\u2019s disease. Science. 2023;382(6676):1242\u20134.","journal-title":"Science"},{"issue":"11","key":"1532_CR4","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/nrneurol.2014.181","volume":"10","author":"PS Sachdev","year":"2014","unstructured":"Sachdev PS, Blacker D, Blazer DG, Ganguli M, Jeste DV, Paulsen JS, et al. Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol. 2014;10(11):634\u201342.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"1532_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/alz.12328","volume":"17","author":"Alzheimer's disease facts and figures","year":"2021","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2021;17(3):327\u2013406.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1532_CR6","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/geront\/gnv130","volume":"55","author":"EM Crimmins","year":"2015","unstructured":"Crimmins EM. Lifespan and Healthspan: Past, Present, and Promise. Gerontologist. 2015;55(6):901\u201311.","journal-title":"Gerontologist"},{"issue":"1","key":"1532_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/WAD.0b013e31819fe7d1","volume":"24","author":"HM Arrighi","year":"2010","unstructured":"Arrighi HM, Neumann PJ, Lieberburg IM, Townsend RJ. Lethality of Alzheimer disease and its impact on nursing home placement. Alzheimer Dis Assoc Disord. 2010;24(1):90\u20135.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"1532_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1532-5415.2005.53118.x","volume":"53","author":"SL Mitchell","year":"2005","unstructured":"Mitchell SL, Teno JM, Miller SC, Mor V. A national study of the location of death for older persons with dementia. J Am Geriatr Soc. 2005;53(2):299\u2013305.","journal-title":"J Am Geriatr Soc"},{"key":"1532_CR9","unstructured":"Program NSR. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 17 Registries, Nov 2022 Sub (2000\u20132020) - Linked To County Attributes - Total U.S., 1969\u20132021 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2023, based on the November 2022 submission. 2022."},{"issue":"6","key":"1532_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ca.980080612","volume":"8","author":"A Alzheimer","year":"1995","unstructured":"Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer\u2019s 1907 paper, \u201cUber eine eigenartige Erkankung der Hirnrinde.\u201d Clin Anat. 1995;8(6):429\u201331.","journal-title":"Clin Anat"},{"issue":"1","key":"1532_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Amieva H, Petersen RC, Chetelat G, Holtzman DM, Hyman BT, et al. Alzheimer disease Nat Rev Dis Primers. 2021;7(1):33.","journal-title":"Alzheimer disease Nat Rev Dis Primers"},{"key":"1532_CR12","doi-asserted-by":"publisher","first-page":"741059","DOI":"10.3389\/fpsyt.2021.741059","volume":"12","author":"CY Kwon","year":"2021","unstructured":"Kwon CY, Lee B. Prevalence of Behavioral and Psychological Symptoms of Dementia in Community-Dwelling Dementia Patients: A Systematic Review. Front Psychiatry. 2021;12:741059.","journal-title":"Front Psychiatry"},{"issue":"6","key":"1532_CR13","doi-asserted-by":"publisher","first-page":"724","DOI":"10.2174\/156720512801322591","volume":"9","author":"FA Schmitt","year":"2012","unstructured":"Schmitt FA, Nelson PT, Abner E, Scheff S, Jicha GA, Smith C, et al. University of Kentucky Sanders-Brown Healthy Brain Aging Volunteers: Donor Characteristics, Procedures, and Neuropathology. Curr Alzheimer Res. 2012;9(6):724\u201333.","journal-title":"Curr Alzheimer Res"},{"issue":"6","key":"1532_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7748\/nop.2021.e1295","volume":"33","author":"B Reid","year":"2021","unstructured":"Reid B, O\u2019Brien L. The psychological effects of caring for a family member with dementia. Nurs Older People. 2021;33(6):21\u20137.","journal-title":"Nurs Older People."},{"issue":"4","key":"1532_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10433-012-0242-8","volume":"9","author":"EM Kessler","year":"2012","unstructured":"Kessler EM, Bowen CE, Baer M, Froelich L, Wahl HW. Dementia worry: a psychological examination of an unexplored phenomenon. Eur J Ageing. 2012;9(4):275\u201384.","journal-title":"Eur J Ageing"},{"key":"1532_CR16","doi-asserted-by":"publisher","first-page":"104246","DOI":"10.1016\/j.archger.2020.104246","volume":"92","author":"P Werner","year":"2021","unstructured":"Werner P, AboJabel H, Maxfield M. Conceptualization, measurement and correlates of dementia worry: A scoping review. Arch Gerontol Geriatr. 2021;92:104246.","journal-title":"Arch Gerontol Geriatr"},{"issue":"4","key":"1532_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jalz.2018.03.002","volume":"14","author":"DS Knopman","year":"2018","unstructured":"Knopman DS, Haeberlein SB, Carrillo MC, Hendrix JA, Kerchner G, Margolin R, et al. The National Institute on Aging and the Alzheimer\u2019s Association Research Framework for Alzheimer\u2019s disease: Perspectives from the Research Roundtable. Alzheimers Dement. 2018;14(4):563\u201375.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1532_CR18","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s11011-021-00733-4","volume":"37","author":"J Zhou","year":"2022","unstructured":"Zhou J, Benoit M, Sharoar MG. Recent advances in pre-clinical diagnosis of Alzheimer\u2019s disease. Metab Brain Dis. 2022;37(6):1703\u201325.","journal-title":"Metab Brain Dis"},{"issue":"1","key":"1532_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1053\/j.seminoncol.2019.01.002","volume":"46","author":"M Burotto","year":"2019","unstructured":"Burotto M, Wilkerson J, Stein WD, Bates SE, Fojo T. Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes. Semin Oncol. 2019;46(1):83\u201399.","journal-title":"Semin Oncol"},{"issue":"4","key":"1532_CR20","first-page":"264","volume":"4","author":"R Doody","year":"2017","unstructured":"Doody R. Developing Disease-Modifying Treatments in Alzheimer\u2019s Disease - A Perspective from Roche and Genentech. J Prev Alzheimers Dis. 2017;4(4):264\u201372.","journal-title":"J Prev Alzheimers Dis"},{"issue":"16","key":"1532_CR21","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1200\/JCO.23.01777","volume":"42","author":"H Xiao","year":"2024","unstructured":"Xiao H, Vaidya R, Hershman DL, Unger JM. Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012\u20132022. J Clin Oncol. 2024;42(16):1953\u201360.","journal-title":"J Clin Oncol"},{"issue":"60","key":"1532_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/jncimonographs\/lgac023","volume":"2022","author":"J Le-Rademacher","year":"2022","unstructured":"Le-Rademacher J, Mohile S, Unger J, Hudson MF, Foster J, Lichtman S, et al. Trial Design Considerations to Increase Older Adult Accrual to National Cancer Institute Clinical Trials. J Natl Cancer Inst Monogr. 2022;2022(60):135\u201341.","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"3","key":"1532_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/jnci\/djaa155","volume":"113","author":"JM Unger","year":"2021","unstructured":"Unger JM, Hershman DL, Till C, Minasian LM, Osarogiagbon RU, Fleury ME, et al. \u201cWhen Offered to Participate\u201d: A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials. J Natl Cancer Inst. 2021;113(3):244\u201357.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1532_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JOP.19.00735","volume":"16","author":"LM Minasian","year":"2020","unstructured":"Minasian LM, Unger JM. What Keeps Patients Out of Clinical Trials? JCO Oncol Pract. 2020;16(3):125\u20137.","journal-title":"JCO Oncol Pract"},{"issue":"17","key":"1532_CR25","doi-asserted-by":"publisher","first-page":"13618","DOI":"10.3390\/ijms241713618","volume":"24","author":"HY Choi","year":"2023","unstructured":"Choi HY, Chang JE. Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs. Int J Mol Sci. 2023;24(17):13618.","journal-title":"Int J Mol Sci."},{"issue":"3","key":"1532_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3171\/jns.1991.74.3.0441","volume":"74","author":"H Brem","year":"1991","unstructured":"Brem H, Mahaley MS Jr, Vick NA, Black KL, Schold SC Jr, Burger PC, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg. 1991;74(3):441\u20136.","journal-title":"J Neurosurg"},{"issue":"12","key":"1532_CR27","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1586\/14737140.2013.840090","volume":"13","author":"A Bregy","year":"2013","unstructured":"Bregy A, Shah AH, Diaz MV, Pierce HE, Ames PL, Diaz D, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert Rev Anticancer Ther. 2013;13(12):1453\u201361.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1532_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.wneu.2024.01.006","volume":"183","author":"MY Ferreira","year":"2024","unstructured":"Ferreira MY, Thomaz de Assis EB, Batista S, Palavani LB, Verly G, Correa EM, et al. Survival Impact of Combined Biguanide and Temozolomide in Glioblastoma Preclinical Models: A Systematic Review and Meta-Analysis. World Neurosurg. 2024;183:239-245.e2.","journal-title":"World Neurosurg."},{"issue":"3","key":"1532_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0895-4356(00)00305-X","volume":"54","author":"DA Braunholtz","year":"2001","unstructured":"Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a \u201ctrial effect.\u201d J Clin Epidemiol. 2001;54(3):217\u201324.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"1532_CR30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/archinternmed.2007.124","volume":"168","author":"SR Majumdar","year":"2008","unstructured":"Majumdar SR, Roe MT, Peterson ED, Chen AY, Gibler WB, Armstrong PW. Better outcomes for patients treated at hospitals that participate in clinical trials. Arch Intern Med. 2008;168(6):657\u201362.","journal-title":"Arch Intern Med"},{"key":"1532_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1471-2288-7-30","volume":"7","author":"R McCarney","year":"2007","unstructured":"McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a randomised, controlled trial. BMC Med Res Methodol. 2007;7:30.","journal-title":"BMC Med Res Methodol"},{"issue":"24","key":"1532_CR32","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","volume":"69","author":"JA Schneider","year":"2007","unstructured":"Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197\u2013204.","journal-title":"Neurology"},{"issue":"9","key":"1532_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13195-014-0082-1","volume":"6","author":"J Rahimi","year":"2014","unstructured":"Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther. 2014;6(9):82.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1532_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123(1):1\u201311.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"1532_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-020-02255-2","volume":"141","author":"J Attems","year":"2021","unstructured":"Attems J, Toledo JB, Walker L, Gelpi E, Gentleman S, Halliday G, et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathol. 2021;141(2):159\u201372.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1532_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology"},{"issue":"5796","key":"1532_CR37","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130\u20133.","journal-title":"Science"},{"issue":"6","key":"1532_CR38","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503\u201327.","journal-title":"Brain."},{"issue":"12","key":"1532_CR39","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1002\/alz.12157","volume":"16","author":"BV Zlokovic","year":"2020","unstructured":"Zlokovic BV, Gottesman RF, Bernstein KE, Seshadri S, McKee A, Snyder H, et al. Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop. Alzheimers Dement. 2020;16(12):1714\u201333.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1532_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-020-02235-6","volume":"141","author":"BL Blevins","year":"2020","unstructured":"Blevins BL, Vinters HV, Love S, Wilcock DM, Grinberg LT, Schneider JA, et al. Brain arteriolosclerosis. Acta Neuropathol. 2020;141(1):1\u201324.","journal-title":"Acta Neuropathol."},{"issue":"1","key":"1532_CR41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3233\/JAD-230425","volume":"94","author":"J Di","year":"2023","unstructured":"Di J, Nelson RS, Jicha GA, Moga DC, Barber JM, Cykowski MD, et al. Urinary Incontinence in a Community-Based Autopsy Cohort Is Associated with Limbic Predominant Age-Related TDP-43 Encephalopathy Neuropathologic Changes. J Alzheimers Dis. 2023;94(1):333\u201346.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"1532_CR42","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362\u201381.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"1532_CR43","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/ana.25380","volume":"85","author":"PA Boyle","year":"2019","unstructured":"Boyle PA, Yu L, Leurgans SE, Wilson RS, Brookmeyer R, Schneider JA, et al. Attributable risk of Alzheimer\u2019s dementia attributed to age-related neuropathologies. Ann Neurol. 2019;85(1):114\u201324.","journal-title":"Ann Neurol"},{"issue":"1","key":"1532_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00401-022-02444-1","volume":"144","author":"PT Nelson","year":"2022","unstructured":"Nelson PT, Brayne C, Flanagan ME, Abner EL, Agrawal S, Attems J, et al. Frequency of LATE neuropathologic change across the spectrum of Alzheimer\u2019s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathol. 2022;144(1):27\u201344.","journal-title":"Acta Neuropathol."},{"issue":"6","key":"1532_CR45","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/alz.12461","volume":"18","author":"GA Jicha","year":"2021","unstructured":"Jicha GA, Abner EL, Arnold SE, Carrillo MC, Dodge HH, Edland SD, et al. Committee on High-quality Alzheimer\u2019s Disease Studies (CHADS) consensus report. Alzheimers Dement. 2021;18(6):1109\u201318.","journal-title":"Alzheimers Dement."},{"issue":"4","key":"1532_CR46","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/alz.13016","volume":"19","author":"Alzheimer's disease facts and figures","year":"2023","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2023;19(4):1598\u2013695.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01532-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01532-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01532-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T08:07:38Z","timestamp":1724314058000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01532-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1532"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01532-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"19 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data from the University of Kentucky of Kentucky Alzheimer\u2019s Disease Research Center were conducted in keeping with a protocol (IRB # 44009) approved by the University of Kentucky Institutional Review Board. All research participants and\/or their caregivers signed appropriate consent forms for participation in the research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}